Home Find a Provider Find a Provider Bradley M. Turner, M.D., M.P.H., M.H.A.

Bradley M. Turner, M.D., M.P.H., M.H.A.

UR Medicine Labs

No ratings currently available, see text in Ratings section below for explanation.

UR Medicine Faculty

Accountable Health Partner

Not Accepting New Patients

Contact

Office (585) 275-3191

Bradley M. Turner, M.D., M.P.H., M.H.A.

View Contact & Scheduling

About Me
Credentials
Research
Publications
Ratings & Comments

About Me

Dr. Turner is board certified in Anatomic and Clinical Pathology, and in Family Medicine. Dr. Turner serves as a faculty member on the breast and gynecologic pathology subspecialty services in the Department of Pathology and Laboratory Medicine at URMC. He provides anatomic pathology services at both Highland Hospital and Strong Memorial Hospital, while also providing clinical pathology services at Highland Hospital. Dr. Turner also provides urgent care consultation services in Rochester New York.

Dr. Turner enjoys his role as a pathologist in the community and often relies on his experience as a family practitioner during his evaluation of cases. "The biggest difference, of course, is the decrease in patient care contact," he has been known to say. "But there's a unique dynamic I often feel with clinicians' as a result of my experience with patient care. The information I provide in a signed out report is grounded in the sincere appreciation of the conundrums that often occur in formulating diagnosis and treatment plans for the patient, including the emotional conflicts that often arise during this decision making process".

Dr. Turner and his wife, Dr. Stella King-Turner, an Associate Professor in the Departments of Emergency Medicine and Family Medicine at URMC, are parents of three children: twins Alyssa and Benjamin, age 13, and Colin, age 10. Dr. Turner also serves on the board of directors of the Anthony L. Jordan Health Corporation, as well as the Black Physicians Network of Greater Rochester, a 501(c)(3) not for profit organization with the vision of "Black physicians partnering with each other and the community to address disparities in healthcare and promote excellence and innovation in our youth." Brad is also very active in his fraternity Sigma Pi Phi, Gamma Iota Chapter. He enjoys music, sports, and reading in his spare time.

Dr. Turner's influences, like his professional assignments, are diverse. Among them: Dr. I-Tien Yeh, previously Director of the Core Pathology lab for the Cancer Research and Therapy Center at University of Texas Health Science Center at San Antonio, and Dr. Fattaneh Tavassoli, Professor of Pathology, Obstetrics, Gynecology, and Reproductive Sciences at Yale School of Medicine. Another is Dr. James Henry, a neuropathologist with a military background whom Dr. Turner said "commanded me to apply to Yale during a chance hallway conversation. He recognized potential in me - and told me. I will always be grateful to him for that. One's destiny can truly be affected by a chance hallway conversation."

And, one more influence: Benjamin Franklin, author of one of Dr. Turners favorite quotes--
"Tell me and I forget, teach me and I may remember, involve me and I learn."

Faculty Appointments

Professor - Department of Pathology and Laboratory Medicine (SMD)

Credentials

Residency & Fellowship

Fellowship, Pathology, Yale New Haven Hospital Temple Medical Center. 2011 - 2012

Fellowship, Surgical Oncology, Roswell Park Cancer Institute. 2010 - 2011

Fellowship, Surgical Pathology, UT Health San Antonio Long School of Medicine. 2009 - 2010

Residency, Pathology, University of Florida College of Medicine. 2005 - 2009

Residency, Family Medicine, Cape Fear Valley Health System. 1998 - 2000

Internship, Family Medicine, Cape Fear Valley Health System. 1997 - 1998

Education

MS | University Of South Florida College of Public Health. 2009

MPH | Umdnj-School Of Public Health-Piscataway. 1999

MD | Umdnj-Graduate School Of Biomedical Sciences-Newark. 1997

Research

Increasing awareness of new prognostic and predictive methodologies, and the introduction of next generation sequencing, clearly has established the role of precision medicine in targeted therapy, particularly for cancer patients. Precision medicine includes combinations of diagnostic testing and treatment options that can be offered to patients at presentation, and potentially throughout the course of their disease as new mutations arise and response to treatment diminishes. Precision targeted therapy for breast cancer treatment remains a challenge, because breast cancer is a disease with significant nonbiologic and biologic diversity. The primary clinical goal in breast cancer treatment is to coordinate the most effective local, regional and systemic treatment regimens, including targeted drug regimens, for each patient. The traditional clinical-pathologic paradigm for risk stratification of patients with breast cancer is based on careful considerations of a combination of clinical and histopathologic factors including patient age, menopausal status, tumor size, histologic type, histologic grade, measures of proliferation, lymphovascular invasion, lymph node staging, and evidence of distant metastasis. Differences in histopathologic features of each breast cancer are related directly to the patients underlying tumor biology and risk for metastasis. The use of the biomarkers, estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), have been invaluable for assessing patient suitability for hormonal or HER2 therapy, thus potentially decreasing a patients risk for recurrence and metastasis; however, the interpretation of these biomarkers is subjective, and the indications for adding chemotherapy are even more challenging. The introduction of multi-gene assays such as Oncotype DX®, and next generation sequencing, has increased our understanding of both tumor biology and clinical behavior, including risks for recurrence and metastasis. These newer technologies offer the possibility for considering more appropriate therapeutic choices, and challenge the relevance of the traditional clinical-pathologic paradigm for selecting the optimal management for a breast cancer patient; however, the cost of these newer technologies is a concern. Several studies have suggested that standard histopathologic variables can provide information similar to that provided by newer technologies, with less of a cost burden to the healthcare system. My work currently focuses on evaluating histologic variables which may provide cost-efficient and cost-effective prognostic and predictive outcome data for breast cancer patients. It has been reported that the tumor microenvironment may affect the Oncotype DX® recurrence score, which has been shown to be both prognostic and predictive of breast cancer recurrence in certain populations of breast cancer patients. In collaboration with Dr. Ed Brown at the University of Rochester (Rochester, NY), Dr. Turner is beginning to explore how components of the tumor microenvironment, such as the extracellular matrix (ECM), may be contributing to breast cancer recurrence and metastasis, and how quantitative analysis of components of the tumor microenvironment such as the ECM can reveal important insights into the process of breast tumor metastasis. In collaboration with Dr. Kate-Rittenhouse-Olson, Dr. Turner is also beginning to explore the value antibodies that potentially target cancer tissue using immunohistochemistry in "in-vivo" models.

Publications

Journal Articles

Catabolism of extracellular glutathione supplies amino acids to support tumor growth.

Hecht F, Zocchi M, Tuttle ET, Ward NP, Smith B, Kang YP, Cazarin J, Soares ZG, Ozgurses ME, Zhao H, Sheehan C, Alimohammadi F, Munger LD, Trivedi D, Asantewaa G, Blick-Nitko SK, Zoeller JJ, Chen Y, Vasiliou V, Turner BM, Muir A, Coloff JL, Munger J, DeNicola GM, Harris IS

bioRxiv : the preprint server for biology.. 2024 October 13 Epub 10/13/2024.

Optimized biomarker evaluation and molecular testing in the era of breast cancer precision medicine.

Hicks DG, Turner BM

Biotechnic & histochemistry : official publication of the Biological Stain Commission.. 2024 October 99 (7):357-369. Epub 09/11/2024.

Breast Cancer With HER2 Immunohistochemical Score 2 and Average HER2 Signals/Cell 6 or More and HER2/CEP17 Ratio Less Than 2 ('ISH Group 3'): A Multi-Institutional Cohort Analysis Emphasizing Outcome and Molecular Subtype.

Ajabnoor R, Zhang G, Hu Y, Gao Y, Finkelman BS, Turner BM, Yi S, Dhakal A, Audeh W, Li Z, Li X, Hicks DG, Zhang H

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.. 2024 August 37 (8):100530. Epub 05/27/2024.

HER2 evaluation for clinical decision making in human solid tumours: pearls and pitfalls.

Zhang H, Finkelman BS, Ettel MG, Velez MJ, Turner BM, Hicks DG

Histopathology.. 2024 July 85 (1):3-19. Epub 03/05/2024.

Performance of HER2 DAKO HercepTest and Ventana 4B5 immunohistochemical assays on detecting HER2 gene-amplification in uterine serous carcinomas.

Navarro Sanchez JM, Finkelman BS, Tyburski H, Turner BM, Moisini I, Katerji H, Varghese S, Wang X, Schiffhauer LM, Chen JJ, Hicks DG, Zhang H

Human pathology.. 2024 June 148 :51-59. Epub 05/11/2024.

In ER-Positive, HER2-Negative Breast Cancers, HER2 mRNA Levels Correlate Better with Clinicopathologic Features and Oncotype DX Recurrence Score than HER2 Immunohistochemistry.

Tyburski H, Karakas C, Finkelman BS, Turner BM, Zhang H, Hicks DG

Laboratory investigation; a journal of technical methods and pathology.. 2024 March 104 (3):100309. Epub 12/20/2023.

Clinical-risk Assessment of ER positive, HER2 Negative Breast Cancer Patients: Correlation between the Average Modified Magee score and MammaPrint

Turner BM; Katerji H; Finkelman BS; Hicks DG; Zhang H.

2024; (in preparation).

FOLR1 and HER2 Expression in Uterine Serous Carcinoma

Finkelman BS; Tyburski? H; Mendoza RP; Zhang H; Navarro JS; Varghese S; Wang X; Katerji H; Schiffhauer LM; Chen J; Hicks DG.

2024; (in preparation).

Human epidermal growth factor receptor 2 (HER2) intratumoral heterogeneity in uterine serous carcinoma: The role of the 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) five breast cancer HER2 FISH groups

Turner BM; Moisini I; Katerji H; Finkelman BS; Hicks DG; Zhang H.

2024; (in preparation).

HER2 Low: Biopsy versus excision

Finkelman BS; Zhang H; Hicks DG; Turner BM.

2024; (in preparation).

Standardizing a Treatment Protocol for Murine Breast Cancer Model: Surgery and Adjuvant Chemotherapy

Olsen T; Pack L; Ashji G; Punreddy A; Turner BM; Beha M; Noble M; Leckenby J.

Journal of Surgical Research. 2024; (in review).

HER2 categorical changes after neoadjuvant chemotherapy: A study of 192 matched breast cancers with the inclusion of HER2-Low category.

Karakas C, Tyburski H, Turner BM, Weiss A, Akkipeddi SMK, Dhakal A, Skinner K, Hicks DG, Zhang H

Human pathology.. 2023 December 142 :34-41. Epub 11/17/2023.

HER2 in uterine serous carcinoma: Current state and clinical perspectives.

Navarro Sanchez JM, Finkelman BS, Turner BM, Katerji H, Wang X, Varghese S, Wang T, Peng Y, Hicks DG, Zhang H

American journal of clinical pathology.. 2023 October 3160 (4):341-351. Epub 1900 01 01.

Interobserver and Interantibody Reproducibility of HER2 Immunohistochemical Scoring in an Enriched HER2-Low-Expressing Breast Cancer Cohort.

Karakas C, Tyburski H, Turner BM, Wang X, Schiffhauer LM, Katerji H, Hicks DG, Zhang H

American journal of clinical pathology.. 2023 May 2159 (5):484-491. Epub 1900 01 01.

Clinicopathologic Predictors of Clinical Outcomes in Mammary Adenoid Cystic Carcinoma: A Multi-institutional Study.

Khoury T, Rosa M, Nayak A, Karabakhtsian R, Fadare O, Li Z, Turner B, Fang Y, Kumarapeli A, Li X, Numbere N, Villatoro T, Wang JG, Sadeghi S, Attwood K, George A, Bhargava R

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.. 2023 February 36 (2):100006. Epub 01/09/2023.

The Rochester Modified Magee Algorithm (RoMMa): An Outcomes Based Strategy for Clinical Risk-Assessment and Risk-Stratification in ER Positive, HER2 Negative Breast Cancer Patients Being Considered for Oncotype DX Testing.

Turner BM, Finkelman BS, Hicks DG, Numbereye N, Moisini I, Dhakal A, Skinner K, Sanders MAG, Wang X, Shayne M, Schiffhauer L, Katerji H, Zhang H

Cancers.. 2023 January 3115 (3)Epub 01/31/2023.

The Evolution of Ki-67 and Breast Carcinoma: Past Observations, Present Directions, and Future Considerations.

Finkelman BS, Zhang H, Hicks DG, Turner BM

Cancers.. 2023 January 2815 (3)Epub 01/28/2023.

Chronic lymphocytic leukemia in the female pelvis: A case series illustrating the diagnostic challenges

Morell A.; Thappa S.; Zhang N.; Rowswell-Turner R.; Marshall L.; Angel C.; DuBeshter B.; Turner B.; Moore R.; Smith A.

Current Problems in Cancer: Case Reports. 2023; 10.

Abnormal Uterine Involution May Lead to Atony and Postpartum Hemorrhage: A Hypothesis, With Review of the Evidence.

Heller DS, Cramer SF, Turner BM

Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.. 2023 26 (5):429-436. Epub 09/06/2023.

HER2-low breast cancers: Current insights and future directions.

Zhang H, Karakas C, Tyburski H, Turner BM, Peng Y, Wang X, Katerji H, Schiffhauer L, Hicks DG

Seminars in diagnostic pathology.. 2022 September 39 (5):305-312. Epub 07/09/2022.

HER2-low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles.

Zhang H, Katerji H, Turner BM, Audeh W, Hicks DG

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.. 2022 August 35 (8):1075-1082. Epub 02/19/2022.

The relationship of myometrial histopathology (metropathy) to myometrial dysfunction and clinical manifestations.

Turner BM, Cramer SF, Heller DS

Annals of diagnostic pathology.. 2022 April 57 :151902. Epub 02/01/2022.

HER2-Low Breast Cancers.

Zhang H, Katerji H, Turner BM, Hicks DG

American journal of clinical pathology.. 2022 March 3157 (3):328-336. Epub 1900 01 01.

Interobserver agreement in the diagnosis of anal dysplasia: comparison between gastrointestinal and gynaecological pathologists and utility of consensus conferences.

Abu-Farsakh S, Drage MG, Huber AR, Turner BM, Varghese S, Wang X, Whitney-Miller CL, Gonzalez RS

Histopathology.. 2022 March 80 (4):648-655. Epub 12/14/2021.

Apoplectic leiomyomas: does ethnicity make a difference? a clinicopathologic study.

Turner BM, Cramer SF, Heller DS, Tavassoli FA

Virchows Archiv : an international journal of pathology.. 2022 March 480 (3):645-654. Epub 11/02/2021.

Second-Harmonic Generation Imaging Reveals Changes in Breast Tumor Collagen Induced by Neoadjuvant Chemotherapy.

Desa DE, Wu W, Brown RM, Brown EB, Hill RL, Turner BM, Brown EB

Cancers.. 2022 February 914 (4)Epub 02/09/2022.

Significance of HER2 in Microinvasive Breast Carcinoma.

Zhang H, Moisini I, Turner BM, Wang X, Dhakal A, Yang Q, Kovar S, Schiffhauer LM, Hicks DG

American journal of clinical pathology.. 2021 June 17156 (1):155-165. Epub 1900 01 01.

Reproducibility of scoring criteria for HER2 immunohistochemistry in endometrial serous carcinoma: a multi-institutional interobserver agreement study.

Buza N, Euscher ED, Matias-Guiu X, McHenry A, Oliva E, Ordulu Z, Parra-Herran C, Rottmann D, Turner BM, Wong S, Hui P

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.. 2021 June 34 (6):1194-1202. Epub 02/03/2021.

The pathogenesis of abnormal uterine bleeding in myopathic uteri.

Turner BM, Cramer SF, Heller DS

Annals of diagnostic pathology.. 2021 June 52 :151726. Epub 03/02/2021.

L1CAM Expression in Recurrent Estrogen Positive/HER2 Negative Breast Cancer: A Novel Biomarker Worth Considering.

Moisini I, Zhang H, D'Aguiar M, Hicks DG, Turner BM

Applied immunohistochemistry & molecular morphology : AIMM. 2021 April 129 (4):287-292. Epub 1900 01 01.

Magee Equations™ and response to neoadjuvant chemotherapy in ER+/HER2-negative breast cancer: a multi-institutional study.

Bhargava R, Esposito NN, O?Connor SM, Li Z, Turner BM, Moisini I, Ranade A, Harris RP, Miller DV, Li X, Moosavi H, Clark BZ, Brufsky AM, Dabbs DJ

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.. 2021 January 34 (1):77-84. Epub 07/13/2020.

The evolution of prognostic and predictive markers in breast cancer." Chinese Journal of New Clinical Medicine (invited review)

Katerji H.; Zhang H.; Hicks DG.; Turner BM.

Chinese Journal of New Clinical Medicine. 2021; 14(12): 1169-1181.

Biomarker and Multigene Assay Testing in ER Positive HER-2 Negative Breast Carcinomas: An International Guidelines-Based Approach

Turner BM.; Katerji H.; Zhang H.; Hicks DG.

Human Pathology Reports. 2021; 26(300574).

Vascular lesions of the breast: Essential pathologic features and diagnostic pitfalls

Zhang H.; Turner BM.; Katerji H.; Hicks D.; Wang X.

Human Pathology Reports. 2021; 26(300570).

Intratumoral heterogeneity of second-harmonic generation scattering from tumor collagen and its effects on metastatic risk prediction.

Desa DE, Strawderman RL, Wu W, Hill RL, Smid M, Martens JWM, Turner BM, Brown EB

BMC cancer.. 2020 December 1020 (1):1217. Epub 12/10/2020.

Applying the New Guidelines of HER2 Testing in Breast Cancer.

Zhang H, Moisini I, Ajabnoor RM, Turner BM, Hicks DG

Current oncology reports.. 2020 April 2922 (5):51. Epub 04/29/2020.

Frequency, Clinicopathologic Characteristics, and Follow-up of HER2-Positive Nonpleomorphic Invasive Lobular Carcinoma of the Breast.

Zhang H, Moisini I, Ajabnoor RM, Turner BM, D'aguiar M, Cai X, Gao S, Yang Q, Wang X, Schiffhauer L, Hicks DG

American journal of clinical pathology.. 2020 April 15153 (5):583-592. Epub 1900 01 01.

A Comparison of Hysterectomies for Bleeding With Hysterectomies for Pain.

Turner BM, Cramer SF, Heller DS

International journal of surgical pathology.. 2020 April 28 (2):153-162. Epub 10/15/2019.

Risk stratification of ER-positive breast cancer patients: A multi-institutional validation and outcome study of the Rochester Modified Magee algorithm (RoMMa) and prediction of an Oncotype DX recurrence score <26.

Turner BM, Gimenez-Sanders MA, Soukiazian A, Breaux AC, Skinner K, Shayne M, Soukiazian N, Ling M, Hicks DG

Cancer medicine. 2019 August 8 (9):4176-4188. Epub 06/14/2019.

Second-harmonic generation directionality is associated with neoadjuvant chemotherapy response in breast cancer core needle biopsies.

Desa DE, Bhanote M, Hill RL, Majeski JB, Buscaglia B, D'Aguiar M, Strawderman R, Hicks DG, Turner BM, Brown EB

Journal of biomedical optics.. 2019 August 24 (8):1-9. Epub 1900 01 01.

Reconsidering "low-risk" criteria for breast cancer recurrence in hormone positive patients.

Turner BM, Hicks DG, Soukiazian A

The breast journal.. 2019 May 25 (3):545-547. Epub 04/10/2019.

Impact of 21-Gene Expression Assay on Staging Estrogen Receptor-Positive HER2-Negative Breast Cancer.

Breaux A, Turner B, Wu X, Rai SN, Riley EC, Mandadi M, Sanders MA

Clinical breast cancer.. 2019 February 19 (1):e261-e269. Epub 10/29/2018.

A novel detection methodology for HER2 protein quantitation in formalin-fixed, paraffin embedded clinical samples using fluorescent nanoparticles: an analytical and clinical validation study.

Hicks DG, Buscaglia B, Goda H, McMahon L, Natori T, Turner B, Soukiazian A, Okada H, Nakano Y

BMC cancer.. 2018 December 1818 (1):1266. Epub 12/18/2018.

Preclinical Analysis of JAA-F11, a Specific Anti-Thomsen-Friedenreich Antibody via Immunohistochemistry and In Vivo Imaging.

Karacosta LG, Fisk JC, Jessee J, Tati S, Turner B, Ghazal D, Ludwig R, Johnson H, Adams J, Sajjad M, Koury S, Roy R, Olson JR, Rittenhouse-Olson K

Translational oncology.. 2018 April 11 (2):450-466. Epub 02/22/2018.

Molecular Pathology and Pre-Analytic Variables: Impact on Clinical Practice from a Breast Pathology Perspective

Turner, BM; Moisini, I, Hicks DG.

Current Pathobiology Reports. 2018; 6.

The value of algorithms predicting the Oncotype DX recurrence score should not be underestimated!

Turner B, Tang P, Hicks D

Breast cancer research and treatment.. 2017 July 164 (1):249-250. Epub 04/13/2017.

Pathologic diagnosis of breast cancer patients: evolution of the traditional clinical-pathologic paradigm toward "precision" cancer therapy.

Turner BM, Hicks DG

Biotechnic & histochemistry : official publication of the Biological Stain Commission.. 2017 92 (3):175-200. Epub 03/20/2017.

Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer.

Kim HS, Umbricht CB, Illei PB, Cimino-Mathews A, Cho S, Chowdhury N, Figueroa-Magalhaes MC, Pesce C, Jeter SC, Mylander C, Rosman M, Tafra L, Turner BM, Hicks DG, Jensen TA, Miller DV, Armstrong DK, Connolly RM, Fetting JH, Miller RS, Park BH, Stearns V, Visvanathan K, Wolff AC, Cope L

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2016 December 2034 (36):4390-4397. Epub 10/31/2016.

Nomogram to predict the likelihood of upgrade of atypical ductal hyperplasia diagnosed on a core needle biopsy in mammographically detected lesions.

Khoury T, Chen X, Wang D, Kumar P, Qin M, Liu S, Turner B

Histopathology.. 2015 July 67 (1):106-20. Epub 02/08/2015.

Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score.

Turner BM, Skinner KA, Tang P, Jackson MC, Soukiazian N, Shayne M, Huston A, Ling M, Hicks DG

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.. 2015 July 28 (7):921-31. Epub 05/01/2015.

Pathologic diagnosis, immunohistochemistry, multigene assays and breast cancer treatment: progress toward "precision" cancer therapy.

Hicks D, Turner B

Biotechnic & histochemistry : official publication of the Biological Stain Commission.. 2015 February 90 (2):81-92. Epub 12/01/2014.

Williams JM. Assessment and management of asthma exacerbation in urgent care: Part 1.

Turner, BM, Williams, JM.

The Journal of Urgent Care Medicine. 2014; 8(6): 9-18.

Assessment and management of asthma exacerbation in urgent care: Part 2.

Turner, BM; Williams, JM.

The Journal of Urgent Care Medicine. 2014; 8(7): 9-15.

Napsin A, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma: evaluation of 1674 cases by tissue microarray.

Turner BM, Cagle PT, Sainz IM, Fukuoka J, Shen SS, Jagirdar J

Archives of pathology & laboratory medicine.. 2012 February 136 (2):163-71. Epub 1900 01 01.

Clinical laboratory detection of AmpC ?-lactamase: does it affect patient outcome?

Rand KH, Turner B, Seifert H, Hansen C, Johnson JA, Zimmer A

American journal of clinical pathology.. 2011 April 135 (4):572-6. Epub 1900 01 01.

Penile myointimoma.

Turner BM, Reith JD, Al-Quran SZ

Journal of cutaneous pathology.. 2009 July 36 (7):817-9. Epub 1900 01 01.

Strongyloides hyperinfection syndrome following simultaneous heart and kidney transplantation.

Mizuno S, Iida T, Zendejas I, Martin TD, Schain DC, Turner B, Fujita S

Transplant international : official journal of the European Society for Organ Transplantation.. 2009 February 22 (2):251-3. Epub 10/13/2008.

The AmpC inhibitor, Syn2190, can be used to reveal extended-spectrum beta-lactamases in Escherichia coli.

Netzel TC, Jindani I, Hanson N, Turner BM, Smith L, Rand KH

Diagnostic microbiology and infectious disease.. 2007 July 58 (3):345-8. Epub 03/26/2007.

Transposition of IS2 into the hemB gene of Escherichia coli K-12.

Lewis LA, Lewis D, Persaud V, Gopaul S, Turner B

Journal of bacteriology.. 1994 April 176 (7):2114-20. Epub 1900 01 01.

Books

The 5-Minute Clinical Consult 2022 (2022)

Chapter: Adenomyosis

Pathology Case Reports: Beyond the Pearls (2021)

Chapter: A 77-Year-Old Female Presenting with a Lesion in the Vaginal Area

Pathology Case Reports: Beyond the Pearls (2021)

Chapter: A 70-Year-Old Male with a Mass Around His Nipple

Pathology Case Reports: Beyond the Pearls (2021)

Chapter: A 63-Year-Old Female Presenting for Annual Screening

Pathology Case Reports: Beyond the Pearls (2021)

Chapter: A 51-Year-Old Woman with a Breast Lump

Bone Cancer: Bone Sarcomas and Bone Metastases - From Bench to Bedside (2021)

Chapter: The histopathology of skeletal metastasis

The 5-Minute Clinical Consult 2021 (2020)

Chapter: Adenomyosis

The 5-Minute Clinical Consult 2021 (2020)

Chapter: Ductal Carcinoma in-situ

The 5-Minute Clinical Consult 2021 (2020)

Chapter: Lipoma

Practical Breast Pathology: Frequently Asked Questions (2019)

Chapter: Metastatic cancer to the breast

The 5-Minute Clinical Consult 2020 (2019)

Chapter: Lipoma

The 5-Minute Clinical Consult 2020 (2019)

Chapter: Ductal Carcinoma in-situ

The 5-Minute Clinical Consult 2019 (2018)

Chapter: Ductal Carcinoma in-situ

The 5-Minute Clinical Consult 2019 (2018)

Chapter: Adenomyosis

The 5-Minute Clinical Consult 2019 (2018)

Chapter: Lipoma

The 5-Minute Clinical Consult 2018 (2017)

Chapter: Ductal Carcinoma in-situ

The 5-Minute Clinical Consult 2018 (2017)

Chapter: Adenomyosis

The 5-Minute Clinical Consult 2018 (2017)

Chapter: Lipoma

The 5-Minute Clinical Consult 2017 (2016)

Chapter: Ductal Carcinoma in-situ

The 5-Minute Clinical Consult 2017 (2016)

Chapter: Adenomyosis

The 5-Minute Clinical Consult 2017 (2016)

Chapter: Lipoma

Family Medicine, Principles and Practice (2016)

Chapter: Breast Cancer

The 5-Minute Clinical Consult 2016 (2015)

Chapter: Ductal Carcinoma in-situ

The 5-Minute Clinical Consult 2016 (2015)

Chapter: Lipoma

The 5-Minute Clinical Consult 2016 (2015)

Chapter: Adenomyosis,

Ratings & Comments

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.